# Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria

> **NCT00371735** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 900 (actual)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **DRUG:** chlorproguanil-dapsone-artesunate
- **DRUG:** chlorproguanil-dapsone

## Key facts

- **NCT ID:** NCT00371735
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00371735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00371735, "Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00371735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*